



**Supplementary Figure 10. *EGR2* knockout enhances the long-term potency and memory function of CAR T-cells *in vivo*.** **A**, Schematic of the tumor rechallenge experiments. **B**, Tumor growth after the first (left) and second (right) NALM6 challenges (Mann-Whitney test,  $n = 10$ ). **C**, Mouse survival after high-dose second tumor challenge (Log-rank test). **D**, Tumor growth inhibition in a prostate cancer model using PSMA-targeting CAR T-cells with *EGR2* or *AAVSI* knockout (KO) compared to control CD19 CAR T-cells (19BBz). The tumor growth was monitored over time using caliper-based measurements in NSG mice ( $n = 8$ ).